Keywords gastroesophageal reflux proton pump inhibitor idiopathic pulmonary fibrosis interstitial lung disease ILD PPI GERD Get full text access Log in, subscribe or purchase for full access. REFERENCES 1. Tossier, C. ∙ Dupin, C. ∙ Plantier, L. ... Hiatal hernia on thoracic computed tomography in pulmonary fibrosis Eur Respir J. 2016 Sep; 48(3):833-842 2. Iftikhar, S. ∙ Alhaddad, S.F. ∙ Paulsingh, C.N. ...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Christopher Ryerson
Clinical care in interstitial lung disease: a critical appraisal of clinical guidance documents
Introduction Interstitial lung diseases (ILDs) are a large group of inflammatory and fibrotic lung conditions with a wide variety of aetiologies. There has been a notable rise in the disease burden of ILD over the last couple of decades, despite regional differences in its prevalence [1, 2]. In 2019, the global incidence of ILD was estimated at 24.2 million [1].
Standardized Clinical Terms and Definitions for Interstitial Lung Disease: A Consensus Statement from the Fleischner Society
REFERENCES 1.American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277-304. 2.Travis WD, Costabel U, Hansell DM, et al.
Comorbidities in the idiopathic pulmonary fibrosis and progressive pulmonary fibrosis trial population: a systematic review and meta-analysis
Introduction Interstitial lung disease (ILD) is a large heterogeneous group of inflammatory and fibrosing conditions affecting the lungs. Idiopathic pulmonary fibrosis (IPF), one of the most common subtypes, is the prototypical chronic progressive ILD with a mean survival of 4 years if untreated [1, 2]. Progressive pulmonary fibrosis (PPF) describes a subgroup of non-IPF ILDs that exhibit a similar disease course and prognosis to IPF [3, 4].
Corticosteroid therapy in fibrotic interstitial lung disease: a modified Delphi survey
To the Editor: Fibrotic interstitial lung diseases (fILD) may have features that suggest inflammatory processes that contribute to disease pathogenesis [1]. A recent systematic review shows that the effectiveness and safety of steroid therapy in fILD are still inadequately understood [2], while steroids are potentially harmful in idiopathic pulmonary fibrosis (IPF) [3].
Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases
Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases
REMAP trials are intended to operate as a perennial platform where new domains and/or factors (interventions) are added when understood to be a research priority and when additional funding to support such an addition is acquired (figure 2).
Reply: The concept and application of the treatable traits approach in interstitial lung disease and other chronic respiratory diseases
Footnotes Conflict of interest: Y.H. Khor reports an investigator grant from NHMRC, during the conduct of the study, and non-financial support from Air Liquide Healthcare, outside the submitted work. C.J. Ryerson reports grants and personal fees from Boehringer Ingelheim and Hoffmann-La Roche, personal fees from Veracyte, Pliant Therapeutics, AstraZeneca, Cipla Ltd and Trevi Therapeutics, and grants from VIDA diagnostics, outside the submitted work.
Occupational interstitial lung diseases
Abstract Millions of workers are exposed to substances known to cause occupational interstitial lung diseases (ILDs), particularly in developing countries. However, the burden of the disease is likely to be underestimated due to under-recognition, under-reporting, or both.
Proteomic Evolution from Acute to Post-COVID-19 Conditions
Download Hi-Res ImageDownload to MS-PowerPointCite This:J. Proteome Res.
Design considerations and implications of findings on progressive pulmonary fibrosis from the prospective Canadian Registry for Pulmonary Fibrosis
Thank you for your interest in spreading the word on European Respiratory Society . NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Thank you for your interest in spreading the word on European Respiratory Society . NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Treatable traits in interstitial lung diseases: a call to action
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Integrating morphology and treatable traits into the management of ILD
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Reply: risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Thank you for your interest in spreading the word on European Respiratory Society . NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study
Highlights • Real world data on antifibrotic use in the setting of FVC decline is needed. • Antifibrotic use after FVC decline is associated with less future FVC decline. • Staying on antifibrotic decreases the odds of FVC decline, transplant, or death. • A minority of patients stop antifibrotic therapy in the setting of FVC decline.
A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease
Christopher J. Ryerson, Tamera J. Corte, Jeffrey L. Myers, Simon L.F. Walsh, Sabina A. Guler European Respiratory Journal 2021 58: 2100276; DOI: 10.1183/13993003.00276-2021 Abstract Fibrotic interstitial lung diseases (ILDs) frequently have nonspecific and overlapping clinical and radiological features, resulting in ∼10–20% of patients with ILD lacking a clear diagnosis and thus being labelled with unclassifiable ILD.
Nocturnal hypoxaemia in interstitial lung disease: a systematic review
Interstitial lung disease Nocturnal hypoxaemia in interstitial lung disease: a systematic review http://orcid.org/0000-0002-5434-9342Yet Hong Khor1,2,3, Yvonne Ng4, Duncan Sweeney1,2, Christopher J Ryerson5,6 1 Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia 2 Institute for Breathing and Sleep, Heidelberg, Victoria, Australia 3 Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia 4 Monash Lung and Sleep, Monash Health,...
Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting
Nicola Sverzellati, Christopher J. Ryerson, Gianluca Milanese, Elisabetta A. Renzoni, Annalisa Volpi, Paolo Spagnolo, Francesco Bonella, Ivan Comelli, Paola Affanni, Licia Veronesi, Carmelinda Manna, Andrea Ciuni, Carlotta Sartorio, Giulia Tringali, Mario Silva, Emanuele Michieletti, Davide Colombi, Athol U.
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities
1. Cottin V Hirani NA Hotchkin DL et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018; 27180076 2. Wijsenbeek M Cottin V Spectrum of fibrotic lung diseases. N Engl J Med. 2020; 383: 958-968 3. Lederer DJ Martinez FJ Idiopathic pulmonary fibrosis. N Engl J Med. 2018; 378: 1811-1823 4. George PM Spagnolo P Kreuter M et al.
A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease
Christopher J. Ryerson, Tamera J. Corte, Jeffrey L. Myers, Simon L. F. Walsh, Sabina A. Guler European Respiratory Journal 2021; DOI: 10.1183/13993003.00276-2021 Abstract Fibrotic interstitial lung diseases (ILDs) frequently have nonspecific and overlapping clinical and radiological features, resulting in approximately 10–20% of patients with ILD lacking a clear diagnosis and thus being labelled with unclassifiable ILD.
Diagnostic Classification of Interstitial Lung Disease in Clinical Practice
Liebow A. Carrington C.B. The interstitial pneumonias. in: Simon M. Potchen E.J. LeMay M. Frontiers of pulmonary radiology. Grune & Stratton, New York1969: 102-141 Katzenstein A.A. Askin F.B. Surgical pathology of non-neoplastic lung disease. Can J Surg. 1997; 40: 394 Müller N.L. Coiby T.V. Idiopathic interstitial pneumonias: high-resolution CT and histologic findings. Radiographics.
Nocturnal hypoxaemia in interstitial lung disease: a systematic review
Interstitial lung disease Nocturnal hypoxaemia in interstitial lung disease: a systematic review http://orcid.org/0000-0002-5434-9342Yet Hong Khor1,2,3, Yvonne Ng4, Duncan Sweeney1,2, Christopher J Ryerson5,6 1Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia 2Institute for Breathing and Sleep, Heidelberg, Victoria, Australia 3Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia 4Monash Lung and Sleep, Monash Health, Clayton,...
Chest x-ray or CT for COVID-19 pneumonia? Comparative study in a simulated triage setting
Nicola Sverzellati, Christopher J Ryerson, Gianluca Milanese, Elisabetta A Renzoni, Annalisa Volpi, Paolo Spagnolo, Francesco Bonella, Ivan Comelli, Paola Affanni, Licia Veronesi, Carmelinda Manna, Andrea Ciuni, Carlotta Sartorio, Giulia Tringali, Mario Silva, Emanuele Michieletti, Davide Colombi, U Athol Wells European Respiratory Journal 2021; DOI: 10.1183/13993003.04188-2020 Abstract Introduction: for the management of patients referred to respiratory triage during the early stages of the...
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs) http://orcid.org/0000-0002-1096-0596Paolo Spagnolo1, http://orcid.org/0000-0002-0546-8310Oliver Distler2, Christopher J Ryerson3, Argyris Tzouvelekis4, Joyce S Lee5, Francesco Bonella6, Demosthenes Bouros7, http://orcid.org/0000-0001-6467-7422Anna-Maria Hoffmann-Vold8, Bruno Crestani9,10, Eric L Matteson11 1 Cardiac, Thoracic and Vascular Sciences and Public Health, University of...
Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society
Martine Remy-Jardin, Christopher J. Ryerson, Mark L. Schiebler, Ann N.C. Leung, James M. Wild, Marius M. Hoeper, Philip O. Alderson, Lawrence R. Goodman, John Mayo, Linda B. Haramati, Yoshiharu Ohno, Patricia Thistlethwaite, Edwin J.R. van Beek, Shandra Lee Knight, David A. Lynch, Geoffrey D.
Patient-reported outcome measures after COVID-19: a prospective cohort study
Alyson W. Wong, Aditi S. Shah, James C. Johnston, Christopher Carlsten, Christopher J.
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs) http://orcid.org/0000-0002-1096-0596Paolo Spagnolo1, http://orcid.org/0000-0002-0546-8310Oliver Distler2, Christopher J Ryerson3, Argyris Tzouvelekis4, Joyce S Lee5, Francesco Bonella6, Demosthenes Bouros7, http://orcid.org/0000-0001-6467-7422Anna-Maria Hoffmann-Vold8, Bruno Crestani9,10, Eric L Matteson11 1Cardiac, Thoracic and Vascular Sciences and Public Health, University of...
Patient-reported outcome measures after COVID-19: a prospective cohort study
Alyson W. Wong, Aditi S. Shah, James C. Johnston, Christopher Carlsten, Christopher J. Ryerson European Respiratory Journal 2020; DOI: 10.1183/13993003.03276-2020 Abstract Over 75% of patients admitted to hospital with COVID-19 have abnormal patient-reported outcome measures 3 months after symptom onset, with a third of patients reporting at least moderate impairment in major dimensions of quality of life.
Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?
Amornpun Wongkarnjana, Christopher J.
Real-world appropriateness of imaging severity thresholds in interstitial lung disease clinical trials
Clinical trials have shown the benefit of nintedanib in multiple forms of fibrotic interstitial lung disease (ILD), and suggested benefit of pirfenidone in progressive unclassifiable fibrotic ILD. 3 Maher TM Corte TJ Fischer A et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society
Essentials ■ Imaging is not indicated in patients with suspected COVID-19 and mild clinical features unless they are at risk for disease progression. ■ Imaging is indicated in a patient with COVID-19 and worsening respiratory status. ■ In a resource-constrained environment, imaging is indicated for medical triage of patients with suspected COVID-19 who present with moderate-severe clinical features and a high pre-test probability of disease.
Transbronchial lung cryobiopsy in ILD: the data we've been waiting for
Improved diagnostics in interstitial lung disease are urgently needed. CT can be diagnostic in suitable clinical contexts, but is frequently not definitive. Surgical lung biopsy (SLB) has historically been the preferred method for lung tissue sampling in interstitial lung disease, but carries non-negligible perioperative risks, 1 Hutchinson JP McKeever TM Fogarty AW Navaratnam V Hubbard RB Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997–2008. Eur Respir J.
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
Christopher J. Ryerson, Martin Kolb, Luca Richeldi, Joyce Lee, Daniel Wachtlin, Susanne Stowasser, Venerino Poletti ERJ Open Research 2019 5: 00127-2018; DOI: 10.1183/23120541.00127-2018 Abstract We conducted a post hoc analysis to assess the potential impact of GAP (gender, age, physiology) stage on the treatment effect of nintedanib in patients with idiopathic pulmonary fibrosis. Outcomes were compared in patients at GAP stage I versus II/III at baseline in the INPULSIS® trials.
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis
Nasreen Khalil, Helene Manganas, Christopher J. Ryerson, Shane Shapera, Andre M. Cantin, Paul Hernandez, Eric E. Turcotte, Joseph M. Parker, John E. Moran, Gary R. Albert, Renata Sawtell, Aline Hagerimana, Pierre Laurin, Lyne Gagnon, Frank Cesari, Martin Kolb European Respiratory Journal 2019 53: 1800663; DOI: 10.1183/13993003.00663-2018 Abstract PBI-4050 is a novel orally active small-molecule compound with demonstrated anti-fibrotic activity in several models of fibrosis, including lung fibrosis.
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis
Nasreen Khalil, Helene Manganas, Christopher J. Ryerson, Shane Shapera, Andre M. Cantin, Paul Hernandez, Eric E. Turcotte, Joseph M. Parker, John E. Moran, Gary R. Albert, Renata Sawtell, Aline Hagerimana, Pierre Laurin, Lyne Gagnon, Frank Cesari, Martin Kolb European Respiratory Journal 2018; DOI: 10.1183/13993003.00663-2018 Abstract PBI-4050, is a novel orally active small-molecule compound, with demonstrated anti-fibrotic activity in several models of fibrosis, including lung fibrosis.
The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?
There is no debate that idiopathic pulmonary fibrosis (IPF) is a devastating disease that has a significant impact on patient morbidity and mortality. Patients with IPF experience symptoms throughout most of their disease, with disabling dyspnoea and cough that reduce quality of life. Most IPF patients eventually succumb to respiratory failure with a median survival of approximately 3 years from the time of diagnosis [1].
Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease
Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease Michele R. Schaeffer, Christopher J. Ryerson, Andrew H. Ramsook, Yannick Molgat-Seon, Sabrina S. Wilkie, Satvir S. Dhillon, Reid A. Mitchell, A. William Sheel, Nasreen Khalil, Pat G. Camp, Jordan A. Guenette European Respiratory Journal 2018 51: 1701726; DOI: 10.1183/13993003.01726-2017
Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence
To the Editor:It is with great interest that we read the recent systematic review by Bell et al. [1] concerning the effects of oxygen therapy on dyspnoea and exercise capacity in patients with interstitial lung disease (ILD). The authors report that, while supplemental oxygen increases exercise capacity, it does not improve dyspnoea.
Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm
AbstractThe goal of this review is to summarise the clinical features, management, and prognosis of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). AE-IPF has previously been defined based on clinical and radiological features that include the subacute onset of dyspnoea, bilateral ground glass changes on chest high-resolution computed tomography, and the absence of an identifiable aetiology.
Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease
Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease Michele R. Schaeffer, Christopher J. Ryerson, Andrew H. Ramsook, Yannick Molgat-Seon, Sabrina S. Wilkie, Satvir S. Dhillon, Reid A. Mitchell, A. William Sheel, Nasreen Khalil, Pat G. Camp, Jordan A. Guenette European Respiratory Journal 2017 49: 1602494; DOI: 10.1183/13993003.02494-2016
P089 Effect of baseline GAP index stage on decline in lung function with nintedanib in patients with idiopathic pulmonary fibrosis (IPF)
P089 Effect of baseline GAP index stage on decline in lung function with nintedanib in patients with idiopathic pulmonary fibrosis (IPF) Christopher Ryerson, Martin Kolb, Luca Richeldi, Joyce Lee, Toshio Kimura, Susanne Stowasser, Venerino Poletti QJM Sep 2016, 109 (suppl 1) S52; DOI: 10.1093/qjmed/hcw127.025
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Christopher
Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack